Targeting metabolic checkpoints—such as PFKFB3, PKM2, miR-33, or lactate-related pathways—may restore metabolic balance, suppress M1 polarization, and promote plaque stability, offering promising therapeutic strategies for atherosclerosis. The gene discussed is PFKFB3; the disease is atherosclerosis.